BioSpace News Archive

Zynerba Pharmaceuticals, Inc., the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, announced the acceptance and oral presentation details of two sets of data at The Society for the Study of Behavioural Phenotypes Conference 2021, which will be held virtually from September 9-10, 2021.

NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced that it will participate in a fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference on September 9th at 12:30 pm Eastern time.

Virios Therapeutics, Inc. announced that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference which is taking place virtually September 13 – 15, 2021.

Dr. Reddy’s Laboratories Ltd. announced that Reddy-Lenalidomide, a generic equivalent to Revlimid® capsules, is approved by Health Canada and has been launched in the Canadian market.

Hypoxemia is a common complication of childhood infections, particularly pneumonia. Pneumonia effects developing countries excessively, and accounted for over 2 million deaths per year globally.

Human skin experiences various changes because of growing age, some of them being thinning, sacking and loss, of elasticity, wrinkles, reduced sebum production, teleangiectasias and pigmentation, actinic keratosis issue.

Common neurological disorders include stroke, Parkinson’s disease, Alzheimer’s disease, Epilepsy, and multiple sclerosis.

The increasing count of neurological disorders serves as a prominent driver for the growth in the neurological biomarkers market.

Orphalan announces FDA acceptance for filing of New Drug Application for trientine tetrahydrochloride for the treatment of Wilson’s Disease

Precision BioSciences, Inc. and Tiziana Life Sciences plc announced an exclusive license agreement to explore Tiziana’s foralumab, a fully human anti-CD3 monoclonal antibody, as an agent to induce tolerance of allogeneic CAR T cells to potentially improve the clinical outcome of CAR T cell therapy.